Tag: Reteplase

In cases of acute myocardial infarction (MI) where primary percutaneous coronary intervention (PCI) is unavailable or delayed, timely reperfusion therapy with a thrombolytic agent is critical for survival. The choice of agent can significantly impact outcomes, so what is the best thrombolytic agent for MI, and what are the key differences between modern options?

Despite its proven benefits, only about 3% to 8.5% of potentially eligible ischemic stroke patients receive tPA, a critical clot-dissolving drug [1.7.2]. Understanding **what is the classification of tPA** is crucial for grasping its life-saving applications and limitations.